Original article: general thoracicAn initial experience with FDG-PET in the imaging of residual disease after induction therapy for lung cancer
Section snippets
Patients and methods
The subjects were identified by systematic queries of the PET and the thoracic surgical databases; search criteria included the administration of induction therapy for biopsy-proven NSCLC followed by an FDG-PET scan at the Memorial Sloan-Kettering Cancer Center followed by the performance of an intrathoracic surgical procedure.
Database analysis
Between July 1, 1996, and August 1, 2000, 1,314 FDG-PET scans were performed on patients with NSCLC at the Memorial Sloan-Kettering Cancer Center. During the same time interval, approximately 290 thoracic explorations with curative intent were performed after the administration of induction therapy for biopsy-proven NSCLC. Of these 290 patients, 56 patients (40 treated with chemotherapy alone, 5 with radiation alone, and 11 with chemoradiation) had been restaged post-induction therapy with
Comment
This retrospective review assesses the accuracy of restaging NSCLC patients after induction therapy with a single FDG-PET scan. Although the patient population was heterogeneous in that radiation and chemotherapy were frequently administered outside the Memorial Sloan-Kettering Cancer Center, and the time of post completion of therapy to PET and operation were not controlled, all FDG-PET scans and operations were performed in a homogeneous manner by members of the thoracic disease management
Acknowledgements
The authors thank Dr Nael Martini for reviewing the manuscript and providing his insightful comments. Supported in part by the Laurent and Alberta Gerschel Foundation.
References (22)
- et al.
Utility of 18F-FDG positron emission tomography scanning on selection of patients for resection of hepatic colorectal metastases
Am J Surg
(1999) - et al.
Potential use of FDG-PET scan after induction chemotherapy in surgically staged IIIa-N2 non-small-cell lung cancera prospective pilot study. The Leuven Lung Cancer Group
Ann Oncol
(1998) - et al.
The effects of preoperative chemotherapy on the resectability of non-small cell lung carcinoma with mediastinal lymph node metastases (N2 M0)
Ann Thorac Surg
(1988) - et al.
Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy, and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer
Lung Cancer
(1998) - et al.
Preresectional chemotherapy in stage IIIA non-small-cell lung cancera 7-year assessment of a randomized controlled trial
Lung Cancer
(1999) - et al.
Preoperative chemotherapy for stage IIIa (N2) lung cancerthe Sloan-Kettering experience with 136 patients
Ann Thorac Surg
(1993) - et al.
Neoadjuvant therapy for surgically staged IIIA N2 non-small cell lung cancer (NSCLC)
Lung Cancer
(1997) - et al.
Repeat mediastinoscopy
Ann Thorac Surg
(1984) - et al.
Remediastinoscopy after induction chemotherapy in non-small cell lung cancer
Ann Thorac Surg
(2000) Revisions in the International System for Staging Lung Cancer
Chest
(1997)